- Home
- PETS vs NSRX Comparison
PETS vs NSRX Comparison
Compare PETS & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PETS | NSRX |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Retail-Drug Stores and Proprietary Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.6M | 53.5M |
| IPO Year | 2003 | N/A |
Fundamental Metrics
Financial Performance| Metric | PETS | NSRX |
|---|---|---|
| Price | $2.59 | $5.00 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.20 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 139.0K | 3.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 18.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $273,800,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $3.99 |
| 52 Week High | $4.32 | $9.99 |
Technical Indicators
Market Signals| Indicator | PETS | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 41.33 |
| Support Level | $2.44 | N/A |
| Resistance Level | $2.93 | $6.39 |
| Average True Range (ATR) | 0.12 | 0.70 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 3.17 | 35.08 |
Price Performance
Historical ComparisonAbout PETS PetMed Express Inc.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.